Sequenced from human survivors of who had experienced a DENV infection during travel to an endemic region.
Alternative Names:
DENV
Reactivity Species : Dengue-Virus Expression Host : HEK-293 Endotoxin Level 1.0 EU/mg as determined by the LAL method Specificity : DENV-2D22 activity is DENV-2 specific and directed against the E homodimer at the DIIIA,+A,glycan loop with serotype specificity on one E protein and DII around the fusion loop on the other E protein. Antibody clone DENV-2D22 was identified as strongly neutralizing, capable of inhibiting infection of DENV-2, and able to bind intact DENV-2 but not DIII or recombinant E. DENV-2D22 also did not bind to E protein by immunoblot. DENV-2D22 is E protein specific based on an escape mutant of DIII at R323G and recognizes a complex quaternary epitope displayed on the intact virus formed by DIII and DII on two different monomers within a single dimer. When the entire DENV-2 DIII region was inserted into the backbone sequence of a DENV-4 molecular clone to create a recombinant virus, DENV-2D22 was capable of binding and neutralization. Only five contact residues differ between DENV-2 and -4 in DIII, and these are likely critical for binding and neutralization. DENV-2D22 had no detectable ability to enhance DENV infection at a typical concentration range in a Ab-dependent enhancement assay, was capable of binding and neutralizing chimeric yellow fever-dengue vaccine virus serotype 2, and blocked viral infection of viremic blood for Ae. aegypti.
Clonality:
Monoclonal
Clone Designation:
[DENV-2D22]
Purity:
>=95% monomer by analytical SEC
* VAT and and shipping costs not included. Errors and price changes excepted
